Key inflection point: topline data readout from the PhaseOut DMD phase 2 trial in Duchenne (DMD) expected in 3Q 2018 Imminent start of a pivotal phase 3 study for ridinilazole in C. difficile infections (CDI) Recent Discuva acquisition reinforces novel antibiotics discovery capabilities Current valuation (market cap of c. $165 mln) undemanding given the stage and commercial potential of Summit's lead programs
03 Apr 2018
Capital Network - Summit Therapeutics PLC - Stock Valuation Undemanding
Sign up for free to access
Get access to the latest equity research in real-time from 12 commissioned providers.
Get access to the latest equity research in real-time from 12 commissioned providers.
Capital Network - Summit Therapeutics PLC - Stock Valuation Undemanding
Summit Therapeutics Inc (SMMT:NAS) | 0 0 0.0%
- Published:
03 Apr 2018 -
Author:
Dr. Riccardo Lowi -
Pages:
5
Key inflection point: topline data readout from the PhaseOut DMD phase 2 trial in Duchenne (DMD) expected in 3Q 2018 Imminent start of a pivotal phase 3 study for ridinilazole in C. difficile infections (CDI) Recent Discuva acquisition reinforces novel antibiotics discovery capabilities Current valuation (market cap of c. $165 mln) undemanding given the stage and commercial potential of Summit's lead programs